Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome. — CFSMEATLAS
Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.
Morris, Matthew C, Cooney, Katherine E, Sedghamiz, Hooman et al. · Clinical therapeutics · 2019 · DOI
Quick Summary
This study used computer modeling to understand how hormones and immune system chemicals become unbalanced in ME/CFS. Researchers measured 17 immune markers in women with ME/CFS before, during, and after exercise, then created detailed mathematical models to predict what other hormones and chemicals might also be out of balance. The models suggested that two existing drugs (rintatolimod and rituximab) might help different subgroups of patients, depending on their specific hormone and immune profiles.
Why It Matters
This study provides a mechanistic framework suggesting that ME/CFS involves dysregulated cross-talk between hormonal and immune systems, which could explain why single-target therapies often fail and why patients are heterogeneous. Identifying patient subtypes based on specific endocrine-immune signatures may enable precision medicine approaches and help predict which treatments might benefit which patients.
Observed Findings
Patients with ME/CFS showed altered peripheral immune marker profiles during and after exercise compared to controls.
Mathematical models fitting the experimental data predicted overexpression of corticotropin-releasing hormone, CXCL8, estrogen, FSH, and interleukin-23 at rest in ME/CFS.
Models predicted underexpression of cortisol, adrenocorticotropic hormone, interferon-gamma, IL-10, IL-17, and IL-1α in ME/CFS.
Multiple distinct regulatory 'regimens' (sets of compensatory mechanisms) satisfied the experimental constraints, suggesting endocrine-immune heterogeneity among patients.
Inferred Conclusions
ME/CFS may involve a pathogenic equilibrium across multiple endocrine and immune regulatory axes, explaining resistance to single-target therapies.
Patients with ME/CFS can be stratified into mechanistically distinct subtypes based on endocrine-immune signatures, with different predicted treatment responses to rintatolimod versus rituximab.
Rintatolimod may preferentially benefit patients with low inflammatory cytokines (IL-1α, IL-17) and low cortisol; rituximab may help those with low catecholamines and higher TNF-α/B-cell activation.
Remaining Questions
Do the predicted hormonal abnormalities (e.g., elevated CRH, altered estrogen, FSH dysregulation) actually occur in ME/CFS patients when directly measured?
Do the identified patient subtypes and their predicted treatment responses hold up in prospective randomized controlled trials of rintatolimod and rituximab?
What This Study Does Not Prove
This computational modeling study does not prove that the predicted endocrine abnormalities actually occur in patients, nor does it establish causal mechanisms. The model predictions require experimental validation through direct measurement of the unmeasured hormones and prospective clinical trials; the inferred patient subtypes and treatment responses remain theoretical until tested in controlled studies.